Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The determination in human plasma of 1-hydroxy-2-naphthoic acid following administration of salmeterol xinafoate.

Journal of pharmaceutical and biomedical analysis·1995
Same author

Phospholipase C-sensitive factor VII complexes in dog plasma.

Thrombosis research·1991
Same author

Ondansetron: pre-clinical safety evaluation.

European journal of cancer & clinical oncology·1989
Same author

An evaluation of the safety of ranitidine during seven years daily oral administration to beagle dogs.

Human toxicology·1989
Same author

Hereditary blood coagulation factor-VII deficiency: a comparison of the defect in beagles from several sources.

Comparative biochemistry and physiology. A, Comparative physiology·1988
Same author

Combined use of an automated sample processor and a polymer-based high-performance liquid chromatographic column to determine the pharmacokinetics of labetalol in man.

Journal of chromatography·1987

Related Experiment Video

Updated: Jul 16, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Dose selection for toxicity studies: a protocol for determining the maximum repeatable dose.

N W Spurling1, P F Carey

  • 1Development Division, Glaxo Group Research Ltd, Ware, Hertfordshire, UK.

Human & Experimental Toxicology
|November 1, 1992
PubMed
Summary

This study introduces a three-stage protocol for dose-ranging studies to determine the maximum repeatable dose (MRD) and preview toxicology of new substances, aiding formal regulatory toxicity study design.

More Related Videos

Experimental Protocol for Using Drosophila As an Invertebrate Model System for Toxicity Testing in the Laboratory
06:00

Experimental Protocol for Using Drosophila As an Invertebrate Model System for Toxicity Testing in the Laboratory

Published on: July 10, 2018

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster
07:02

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster

Published on: March 24, 2023

Related Experiment Videos

Last Updated: Jul 16, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Experimental Protocol for Using Drosophila As an Invertebrate Model System for Toxicity Testing in the Laboratory
06:00

Experimental Protocol for Using Drosophila As an Invertebrate Model System for Toxicity Testing in the Laboratory

Published on: July 10, 2018

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster
07:02

Assessment of Chemical Toxicity in Adult Drosophila Melanogaster

Published on: March 24, 2023

Area of Science:

  • Pharmacology
  • Toxicology
  • Drug Development

Background:

  • Formal regulatory toxicity studies (2-4 weeks) are crucial for new drug development.
  • Designing these studies requires accurate dose selection and understanding of toxicokinetics.
  • Current methods may lack efficiency in early-stage substance evaluation.

Purpose of the Study:

  • To present a novel three-stage protocol for dose-ranging studies.
  • To define the maximum repeatable dose (MRD) for new pharmacologically active substances.
  • To generate essential toxicokinetic (TK) data for optimizing formal study designs.

Main Methods:

  • A three-stage protocol (A, B, C) for dose-ranging and TK data generation.
  • Stage A: Provisional MRD determination and basic TK data.
  • Stage B: Daily dosing for ≥7 days to substantiate MRD and gather extensive TK data.
  • Stage C: Single-dose administration at identified levels to correlate dose with TK data.

Main Results:

  • The protocol efficiently determines the maximum repeatable dose (MRD).
  • Comprehensive toxicokinetic (TK) data is generated, informing formal study protocols.
  • The protocol can be executed with minimal animal use (e.g., 24 rats or 6 dogs).
  • Early termination of development is possible for highly toxic substances based on protocol findings.

Conclusions:

  • This dose-ranging protocol effectively previews toxicology and establishes the MRD.
  • Integrated TK data significantly aids in selecting appropriate dose levels for formal toxicity studies.
  • The protocol offers an efficient and resource-conscious approach to early drug development evaluation.